Hoyoung Huh - Nov 14, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director, 10%+ Owner
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact
Stock symbol
AKTX
Transactions as of
Nov 14, 2024
Transactions value $
$0
Form type
3
Date filed
11/22/2024, 04:30 PM
Previous filing
Jun 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 7.61B Nov 14, 2024 Direct F1
holding AKTX Ordinary Shares, par value $0.0001 per share 219M Nov 14, 2024 By Hannol Ventures LLC F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Warrants (Right to Buy) Nov 14, 2024 Ordinary Shares, par value $0.0001 per share 103M $0.00 Direct F1
holding AKTX Stock Option (Right to Buy) Nov 14, 2024 Ordinary Shares, par value $0.0001 per share 704M $0.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
F2 Shares held by Hannol Ventures LLC, of which the Reporting Person is the sole member. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
F3 Subject to the Reporting Person's continued service with the Issuer and there being an effective Form S-8 Registration Statement (a "Form S-8") on file with the SEC covering the issuance of the Ordinary Shares underlying such option, this option shall vest with respect to one third of the underlying shares on each of (i) the effective date of the Form S-8, (ii) December 31, 2024 and (iii) December 31, 2025.

Remarks:

Exhibit 24 - Power of Attorney